Key points are not available for this paper at this time.
On February 9, the Drug Safety and Risk Management Advisory Committee of the FDA voted to recommend a “black-box” warning describing the cardiovascular risks of stimulant drugs used to treat ADHD. Dr. Steven Nissen explains why the advisory committee took decisive action.
Steven E. Nissen (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: